Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
about
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibMutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasThe distinctive nature of adenocarcinoma of the lungProgress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancerMutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature reviewCombating acquired resistance to tyrosine kinase inhibitors in lung cancerSystems pharmacology of complex diseasesIrreversible EGFR-TKIs: dreaming perfectionStructural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerMolecular pathology of lung cancer: key to personalized medicine.Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Epidermal growth factor signaling in transformed cellsLoss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cellsTranscriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations.Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status.Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops.The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradationCRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.Apoptosis block as a barrier to effective therapy in non small cell lung cancerA phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLCComplex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications.EGFR-mutated lung cancer: a paradigm of molecular oncology.Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.The HER family and cancer: emerging molecular mechanisms and therapeutic targets.Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas.Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours.Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer.Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.Muscarinic receptor agonists stimulate human colon cancer cell migration and invasion.Tyrosine kinase inhibitors: Multi-targeted or single-targeted?Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities
P2860
Q24646295-3D04890E-7122-4717-B7F6-6D3CB3492ADEQ24669579-D3F12F5C-4B11-441E-81E2-0D8C612D6B0BQ26781159-E677A30F-A6E8-49EA-9068-0FDAB18B4F20Q26784298-5F091E3F-245A-42FF-9948-E11ADB7183F6Q26785713-8F17C4BA-55B4-4AE9-B742-23E3BA2A5038Q26824877-BEBE93DA-6D60-454D-B13A-E5ABD19C7D59Q26830739-7D269F05-488E-4793-8C6A-49AEF1C22851Q26866186-018AE1DF-FD58-463F-B924-4E95D5E52C99Q27680966-FF6062A3-A66F-4EB5-9192-643B672A77ADQ27691299-F94C0633-CD8C-4124-870E-1A5DAECD4115Q27851566-1220D266-6358-48E2-8129-DD7E81499B3CQ27852979-DA1C16ED-5115-4834-9E79-FAA579ACB34DQ27853214-042DFB00-F282-4614-B7EA-CA91A5EE6D2DQ28084034-552206AE-09AB-4072-8F74-0E71CBF31E94Q28481370-53384024-AC88-4B2B-8253-DED01F72701EQ33306709-FC1D512F-E26A-4416-B757-1DE94BBB2D62Q33332189-D1C97D54-90D8-458D-AEFE-2DB55AB5C8C5Q33733522-67FC2044-3CC7-4AE9-A406-C5901131D1A2Q33769820-30C9EFB9-20ED-469E-AADE-F0953928825AQ33778905-E6476A44-2DCD-45EB-85D7-28C8B60A6A5AQ33808203-62C7FD36-AA35-4440-8882-4996A70BC4B9Q33945734-E9599C88-A6AA-4C05-A201-2DAF4D8DB6B7Q34002791-CB965EB1-5231-44C6-9A77-19AC86731555Q34031203-571F14A9-AEA4-4D69-95E4-45E5C565F528Q34132643-CD8EF1E7-FF6B-4800-B1D0-310591A19B04Q34250003-FCE6053E-CABB-4F53-B527-8F6F8D0CF921Q34254343-5A36929F-9FCF-48B7-83CE-9F7499C5285EQ34311186-A0EFC510-C489-48BA-9BAE-F3DC2572C9AEQ34359601-05352ECB-C2FA-426D-BAA6-9B8C6BDFC30FQ34406334-D74A9652-B6E1-4BE6-9258-74F6F507C477Q34501686-7C5DC050-A5EA-42D2-8E7C-158B0E04AB91Q34558080-AD1A8440-342F-4F13-ACAA-23B9DC8BE0D1Q34567984-12CE7BAB-54AF-4D81-892E-573E70121683Q34634536-F34A6455-C5B3-4F38-A54F-AFE1C9ACE238Q34639632-9D2AAD59-DA31-4A6C-BEBA-BC9CE0D51D0EQ34762839-37A657B0-7F64-4B36-ADAD-6E2E463EA0F2Q34979987-8AB9C214-ABF0-4C31-A027-1C3A896A1789Q34983846-53712C59-330D-4BCB-B897-8B8DDC754151Q35107524-F9B350C2-1D38-45AF-A439-FE953A19321DQ35146927-FFFB0610-3E56-42CE-A75D-D28905814E08
P2860
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
@ast
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
@en
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
@nl
type
label
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
@ast
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
@en
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
@nl
prefLabel
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
@ast
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
@en
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
@nl
P2093
P1476
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
@en
P2093
Gregory J Riely
Katerina A Politi
Vincent A Miller
P304
P356
10.1158/1078-0432.CCR-06-0658
P407
P50
P577
2006-12-01T00:00:00Z